Safety and Immunogenicity of H1N1 Vaccine With Trivalent... | NCT00985673

Safety and Immunogenicity of H1N1 Vaccine With Trivalent... | NCT00985673 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Flulaval/placebo/unadjuvanted Arepanrix Group	Experimental	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.	Biological: GSK2340273A Biological: Seasonal trivalent influenza vaccine (TIV) Biological: Saline placebo
Flulaval/placebo/Arepanrix Group	Experimental	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.	Biological: GSK2340274A Biological: Seasonal trivalent influenza vaccine (TIV) Biological: Saline placebo
Flulaval/unadjuvanted Arepanrix/placebo Group	Experimental	subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.	Biological: GSK2340273A

Interventions

Name	Type	Description	Arm Group Labels	Other Names
GSK2340274A	Biological	Two intramuscular injections	Arepanrix/placebo/Flulaval Group Flulaval/Arepanrix/placebo Group Flulaval/placebo/Arepanrix Group

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.	The A/California vaccine virus-homologous antibody response was measured in subjects having received Flulaval vaccine co-administered with the first dose of Arepanrix vaccine, and in subjects having received two doses of Arepanrix vaccine alone. Titers were expressed as geometric mean antibody titers (GMTs).	21 days after the second dose of Arepanrix vaccine (at Day 42).
Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.	The A/California vaccine virus-homologous antibody response was measured in subjects having received Flulaval vaccine co-administered with the first dose of the unadjuvanted formulation of Arepanrix vaccine, and in subjects having received two doses of the unadjuvanted formulation of Arepanrix vaccine alone. Titers were expressed as geometric mean antibody titers (GMTs).	21 days after the second dose of the unadjuvanted formulation of Arepanrix vaccine (at Day 42)

Secondary Outcomes

Measure	Description	Time Frame
Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).	Influenza-specific CD4 T-Cells were stimulated in vitro with A/California virus and seasonal Influenza viruses, related antigens or derived peptides. Stimulating antigens were A/Brisbane, A/California, pool peptides H1N1 and pool FLU.

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Subjects who the investigator believes can and will comply with the requirements of the protocol.
Written informed consent obtained from the subject.
Male or female adults, 19-40 years of age at the time of the first vaccination.
Safety laboratory tests results within the parameters specified in the protocol.
Satisfactory baseline medical assessment by physical examination.
Comprehension of the study requirements, ability to comprehend and comply with procedures for collection of safety data, expressed availability for the required study period, and ability and willingness to attend scheduled visits as documented by signature on the informed consent document.
Access to a consistent means of telephone contact, which may be either in the home or at the workplace, land line, or mobile, but NOT a pay phone or other multiple-user device.
Female subjects of non-childbearing potential may be enrolled in the study.
Female subjects of childbearing potential may be enrolled in the study, if the subject:
has practiced adequate contraception for 30 days prior to vaccination, and
has a negative pregnancy test on the day of first vaccination, and
has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.

Exclusion Criteria:

Previous vaccination with an H1N1v-like virus vaccine or a medical history of physician-confirmed infection with an H1N1v-like virus.
Prior receipt at any time of any seasonal influenza vaccine.
Planned administration of any vaccine not foreseen by the study protocol between Day 0 and the Day 63 phlebotomy.
Administration of any licensed vaccine within 4 weeks before the first study vaccine dose.
Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
Receipt of systemic glucocorticoids within one month prior to study enrolment, or any other cytotoxic or immunosuppressive drug within six months of study enrolment. Topical, intra-articularly injected, or inhaled glucocorticoids, topical calcineurin inhibitors or imiquimod are allowed.
Receipt of any immunoglobulins and/or any blood products within three months of study enrolment or planned administration of any of these products during the study period.
Presence of evidence of substance abuse or of neurological or psychiatric diagnoses which, even if stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.
Presence of a temperature >= 38.0ºC (>=100.4ºF), or acute symptoms greater than "mild" severity on the scheduled date of first vaccination.
Diagnosed with cancer, or treatment for cancer, within 3 years.
Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
Any significant disorder of coagulation or treatment with warfarin derivatives or heparin. Persons receiving individual doses of low molecular weight heparin outside of 24 hours prior to vaccination are eligible. Persons receiving prophylactic antiplatelet medications, e.g., low-dose acetylsalicylic acid, and without a clinically-apparent bleeding tendency, are eligible.
An acute evolving neurological disorder or history of Guillain-Barré syndrome within six weeks of receipt of seasonal influenza vaccine.
Any known or suspected allergy to any constituent of influenza vaccines; a history of anaphylactic-type reaction to any constituent of influenza vaccines; or a history of severe adverse reaction to a previous influenza vaccine.
Known pregnancy or a positive urine beta-human chorionic gonadotropin test result prior to first vaccination.
Lactating or nursing women.

Contacts/Locations Module

Name	Affiliation	Role
GSK Clinical Trials	GlaxoSmithKline	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
GSK Investigational Site		Stockbridge	Georgia	30281	United States
GSK Investigational Site

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
32889792	Derived	Friel D, Co M, Ollinger T, Salaun B, Schuind A, Li P, Walravens K, Ennis FA, Vaughn DW. Non-neutralizing antibody responses following A(H1N1)pdm09 influenza vaccination with or without AS03 adjuvant system. Influenza Other Respir Viruses. 2021 Jan;15(1):110-120. doi: 10.1111/irv.12780. Epub 2020 Sep 5.
23110320	Derived

Label	URL
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.	View source

ID	Type	URL	Comment
113536	Dataset Specification	View IPD

Results Section

Participant Flow Module

Arm/Group Information

ID	Title	Description
FG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Type	Comment	Reasons
Lost to Follow-up		FG0006 subjects FG0017 subjects FG0026 subjects FG00310 subjects FG0045 subjects FG0053 subjects
Withdrawal by Subject		FG0000 subjects FG0014 subjects FG0025 subjects FG0032 subjects FG004
Other		FG0001 subjects FG0010 subjects FG0021 subjects FG0030 subjects FG004

Arm/Group Information

ID	Title	Description
BG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
BG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
BG002	Flulaval/Unadjuvanted Arepanrix/Placebo Group	subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
BG003	Flulaval/Arepanrix/Placebo Group	subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
BG004	Unadjuvanted Arepanrix/Placebo/Flulaval Group	subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
BG005	Arepanrix/Placebo/Flulaval Group	subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
BG006	Total	Total of all reporting groups

Baseline Measures

Title

Description

Population Description

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Denominator Units Selected

Denominators

Classes

Age, Continuous

Mean

Standard Deviation

Years

Title

Denominators

Categories

Title	Measurements
	BG00029.7± 6.20 BG00128.6± 6.24 BG00228.2± 6.32 BG003

Sex: Female, Male

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Female	BG00053 BG00162 BG002

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.

The A/California vaccine virus-homologous antibody response was measured in subjects having received Flulaval vaccine co-administered with the first dose of Arepanrix vaccine, and in subjects having received two doses of Arepanrix vaccine alone.

Titers were expressed as geometric mean antibody titers (GMTs).

The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.

Posted

Geometric Mean

95% Confidence Interval

Titers

21 days after the second dose of Arepanrix vaccine (at Day 42).

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG002	Flulaval/Unadjuvanted Arepanrix/Placebo Group	subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG003	Flulaval/Arepanrix/Placebo Group	subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG004	Unadjuvanted Arepanrix/Placebo/Flulaval Group	subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG005	Arepanrix/Placebo/Flulaval Group	subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Units	Counts
Participants	OG0000 OG0010 OG0020 OG003

Title

Denominators

Categories

Title	Measurements
	OG003589.8(517.8 to 671.8) OG005933.1(815.6 to 1067.6)

Primary

Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.

The A/California vaccine virus-homologous antibody response was measured in subjects having received Flulaval vaccine co-administered with the first dose of the unadjuvanted formulation of Arepanrix vaccine, and in subjects having received two doses of the unadjuvanted formulation of Arepanrix vaccine alone.

Titers were expressed as geometric mean antibody titers (GMTs).

Posted

Geometric Mean

95% Confidence Interval

Titers

21 days after the second dose of the unadjuvanted formulation of Arepanrix vaccine (at Day 42)

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).

Influenza-specific CD4 T-Cells were stimulated in vitro with A/California virus and seasonal Influenza viruses, related antigens or derived peptides.

Stimulating antigens were A/Brisbane, A/California, pool peptides H1N1 and pool FLU.

The According-To-Protocol (ATP) cohort for immunogenicity at Day 182 included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) for whom 1 dose of Flulaval vaccine and 2 doses of pandemic vaccine were administered and results were available for antibodies against H1N1 antigen at day 182.

Posted

Mean

Standard Deviation

Number of T cells/million

On Days 0, 7, 21, 28, 42, 63 and 182

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).

Influenza-specific CD8 T-Cells were stimulated in vitro with A/California virus and seasonal Influenza viruses, related antigens or derived peptides.

Stimulating antigens were A/Brisbane, A/California, pool peptides H1N1 and pool FLU.

Posted

Mean

Standard Deviation

Number of T cells/million

On Days 0, 7, 21, 28, 42, 63 and 182

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed

Laboratory parameters assessed were alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), alkaline phosphatase (AP), bilirubin (BIL) (total (T)), basophils (BAS). For each parameter and for each range it was assessed whether the values of the subjects were in unkown, above, below or within the range.

The Total Vaccinated Cohort included all vaccinated subjects.

Posted

Number

Subjects

On Days 0, 7, 21, 28, 42, 63 and 182

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed

Laboratory parameters assessed were creatinine (CREA), bilirubin (BIL) (direct (D)), eosinophils (EOS), hemoglobin (Hgb), hematocrit (Hct). For each parameter and for each range it was assessed whether the values of the subjects were unknown, in above, below or within the range.

The Total Vaccinated cohort included all vaccinated subjects

Posted

Number

Subjects

On Days 0, 7, 21, 28, 42, 63 and 182

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Number of Subjects Reporting Solicited Local Symptoms.

Solicited local symptoms assessed were pain, redness and swelling

The Total Vaccinated cohort included all vaccinated subjects

Posted

Number

Subjects

During a 7-day follow-up period (Days 0-6) post-vaccination period

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG002	Flulaval/Unadjuvanted Arepanrix/Placebo Group

Secondary

Number of Subjects Reporting Solicited General Symptoms.

Solicited general symptoms assessed were fatigue, headache, joint pain at other location, muscle aches, shivering, sweating and temperature. Temperature is defined as an axillary temperature equal to or above 38.0 degrees Celsius (°C).

The Total Vaccinated cohort included all vaccinated subjects

Posted

Number

Subjects

During a 7-day follow-up period (Days 0-6) post-vaccination period

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed

Laboratory parameters assessed were serum urea nitrogen (SUN), white blood cells (WBC), red blood cells (RBC). For each parameter and for each range it was assessed whether the values of the subjects were unknown, above, below or within the range.

The Total Vaccinated cohort included all vaccinated subjects

Posted

Number

Subjects

On Days 0, 7, 21, 28, 42, 63 and 182

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Number of Subjects Reporting Unsolicited Adverse Events (AEs).

An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

The Total Vaccinated Cohort included all vaccinated subjects.

Posted

Number

Subjects

Within the 84-day (Days 0-83) post-vaccination period.

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Number of Subjects Reporting Medically Attended Visits (MAEs).

The day 368 was the last contact day for the last subject reporting the event. For each solicited and unsolicited symptom the subject experienced, the subject was asked if they received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel for any reason.

The Total Vaccinated Cohort included all vaccinated subjects.

Posted

Number

Subjects

During the entire study period (Days 0-368).

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Number of Subjects Reporting Potential Immune Diseases (pIMDs).

The day 406 was the last contact day with the subjects reporting the event. Potential immune-mediated diseases (pIMDs) are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.

The Total Vaccinated Cohort included all vaccinated subjects.

Posted

Number

Subjects

During the entire study period (Days 0-406).

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Number of Subjects Reporting Serious Adverse Events (SAEs).

The day 329 was the last contact day with the subjects reporting serious adverse events.

SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.

The Total Vaccinated Cohort included all vaccinated subjects.

Posted

Number

Subjects

During the entire study period (Days 0-329).

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed

Laboratory parameters assessed were neutrophils (NEU), lymphocytes (LYM), monocytes (MON) and platelets (PLA). For each parameter and for each range it was assessed whether the values of the subjects were unknown, in above, below or within the range.

The Total Vaccinated cohort included all vaccinated subjects

Posted

Number

Subjects

On Days 0, 7, 21, 28, 42, 63 and 182

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Microneutralization Antibody Titers Against A/California/7/2009 (H1N1) Strain.

Titers were expressed as geometric mean titers (GMTs) and measured by microneutralization.

Arepanrix vaccine strain and the unadjuvanted formulation of Arepanrix vaccine strain was A/California/7/2009 (H1N1).

Microneutralization testing was cancelled.

Posted

On Days 0, 21, 42, 63 and 182

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG002

Secondary

Number of Subjects With a Microneutralization Titer Greater Than or Equal to 1:28 for Antibodies Against A/California/7/2009 (H1N1) Strain.

Arepanrix vaccine strain and the unadjuvanted formulation of Arepanrix vaccine strain was A/California/7/2009 (H1N1).

The antibody cut-off value assessed was a titer of 1:10 and this value was considered as seropositivity.

Seronegative subject is a subject whose antibody titer is below the cut-off value, a seropositive subject is a subject whose antibody titer is greater than or equal to the cut-off value. Microneutralization titers < 1:28 were considered below the cut-off.

Microneutralization testing was cancelled.

Posted

On Days 0, 21, 42, 63 and 182

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Vaccine Response Rates (VRR) for Microneutralization Antibody Titers Against A/California/7/2009 (H1N1) Strain.

Arepanrix vaccine strain and the unadjuvanted formulation of Arepanrix vaccine strain was A/California/7/2009 (H1N1).

Vaccine Response Rate for microneutralization titers was defined as the incidence rate of vaccinees with at least a 4-fold increase in post vaccination reciprocal titer relative to Day 0.

Microneutralization testing was cancelled.

Posted

On Days 0, 21, 42, 63 and 182

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.

The A/California vaccine virus-homologous antibody response was measured in subjects having received two doses of Arepanrix vaccine, with prior treatment with Flulaval vaccine 21 days before the first dose and in subjects having received two doses of Arepanrix vaccine alone.

Titers were expressed as geometric mean antibody titers (GMTs).

Posted

Geometric Mean

95% Confidence Interval

Titers

21 days after the second dose of Arepanrix vaccine (Day 63 for Flulaval/placebo/Arepanrix Group and Day 42 for Arepanrix/placebo/Flulaval Group)

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group

Secondary

Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.

The A/California vaccine virus-homologous antibody response was measured in subjects having received two doses of the unadjuvanted formulation of Arepanrix vaccine, with prior treatment with Flulaval vaccine 21 days before the first dose and in subjects having received two doses of the unadjuvanted formulation of Arepanrix vaccine alone.

Titers were expressed as geometric mean antibody titers (GMTs).

Posted

Geometric Mean

95% Confidence Interval

Titers

21 days after the second dose of the unadjuvanted formulation of Arepanrix vaccine (Day 63 for Flulaval/placebo/unadjuvanted Arepanrix Group and Day 42 for Unadjuvanted Arepanrix/placebo/Flulaval Group)

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group

Secondary

Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.

The A/California vaccine virus-homologous antibody response was measured in subjects pre-treated with Flulaval who subsequently received two doses of the unadjuvanted formulation of Arepanrix vaccine compared to subjects pre-treated with Flulaval vaccine who subsequently received two doses of Arepanrix vaccine.

Titers were expressed as geometric mean antibody titers (GMTs).

Posted

Geometric Mean

95% Confidence Interval

Titers

21 days after the second dose of the pandemic vaccine (at Day 63)

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.

The antibody response against each of the three Flulaval vaccine components in subjects exposed to co-administration of Flulaval vaccine with the first of two doses of Arepanrix vaccine and in subjects exposed to a single dose of Flulaval vaccine.

Flulaval vaccine strains were Flu A/Brisbane/59/2007 H1N1, Flu A/Uruguay/716/2007 H3N2 and Flu B/Brisbane/60/2008.

Titers were expressed as geometric mean antibody titers (GMTs).

Posted

Geometric Mean

95% Confidence Interval

Titers

21 days after the Flulaval vaccination (at Day 21).

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.

The antibody response against each of the three Flulaval vaccine components in subjects exposed to co-administration of Flulaval vaccine with the first of two doses of the unadjuvanted formulation of Arepanrix vaccine and in subjects exposed to a single dose of Flulaval vaccine.

Flulaval vaccine strains were Flu A/Brisbane/59/2007 H1N1, Flu A/Uruguay/716/2007 H3N2 and Flu B/Brisbane/60/2008.

Titers were expressed as geometric mean antibody titers (GMTs).

Posted

Geometric Mean

95% Confidence Interval

Titers

21 days after the Flulaval vaccination (at Day 21).

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group

Secondary

Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.

The antibody response against each of the three Flulaval vaccine components in subjects exposed to pre-treatment with two doses of Arepanrix vaccine and in subjects exposed to a single dose of Flulaval vaccine.

Flulaval vaccine strains were Flu A/Brisbane/59/2007 H1N1, Flu A/Uruguay/716/2007 H3N2 and Flu B/Brisbane/60/2008.

Titers were expressed as geometric mean antibody titers (GMTs).

Posted

Geometric Mean

95% Confidence Interval

Titers

21 days after the Flulaval vaccination (Day 63 for Arepanrix/placebo/Flulaval Group and Day 21 for Flulaval/placebo/unadjuvanted Arepanrix and Flulaval/placebo/Arepanrix Groups)

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group

Secondary

Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.

The antibody response against each of the three Flulaval vaccine components in subjects exposed to pre-treatment with two doses of the unadjuvanted formulation of Arepanrix vaccine and in subjects exposed to a single dose of Flulaval vaccine.

Flulaval vaccine strains were Flu A/Brisbane/59/2007 H1N1, Flu A/Uruguay/716/2007 H3N2 and Flu B/Brisbane/60/2008.

Titers were expressed as geometric mean antibody titers (GMTs).

Posted

Geometric Mean

95% Confidence Interval

Titers

21 days after the Flulaval vaccination (Day 63 for Unadjuvanted Arepanrix/placebo/Flulaval Group and Day 21 for Flulaval/placebo/unadjuvanted Arepanrix and Flulaval/placebo/Arepanrix Groups)

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group

Secondary

Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.

Titers were expressed as geometric mean antibody titers (GMTs).

Posted

Geometric Mean

95% Confidence Interval

Titers

On Days 0, 21, 42 and 63

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.

Titers were expressed as geometric mean antibody titers (GMTs).

Posted

Geometric Mean

95% Confidence Interval

Titers

At Day 182

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Number of Seroconverted Subjects for Antibodies Against A/ California Strain.

Seroconversion rate was defined as the incidence rate of vaccinees who had either a pre-vaccination titer recorded as < 1:10 and a post-vaccination reciprocal titer ≥ 40 or a pre-vaccination reciprocal titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer.

Seroconversion defined as:

For initially seronegative subjects, antibody titer ≥ 1:40 after vaccination For initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer

Posted

Number

Subjects

At Day 63 from Day 21 for Flulaval/placebo/unadjuvanted Arepanrix and Flulaval/placebo/Arepanrix Groups; At Day 42 from Day 0 for the 4 other groups

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group

Secondary

Number of Seroprotected Subjects for Antibodies Against A/California Strain.

Seroprotection rate was defined as the proportion of subjects with H1N1 reciprocal HI titers ≥ 40 against the tested vaccine virus.

Posted

Number

Subjects

At Day 63 for Flulaval/placebo/unadjuvanted Arepanrix and Flulaval/placebo/Arepanrix Groups; At Day 42 for the 4 other groups.

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Seroconversion Factor for Antibodies Against A/California Strain.

Seroconversion factor was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the prevaccination reciprocal HI titer.

Posted

Mean

95% Confidence Interval

Fold

At Day 63 from Day 21 for Flulaval/placebo/unadjuvanted Arepanrix and Flulaval/placebo/Arepanrix Groups; At Day 42 from Day 0 for the 4 other groups

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains.

Seroconversion defined as:

For initially seronegative subjects, antibody titer ≥ 1:40 after vaccination For initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer

Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.

For the analysis the Flulaval/placebo/unadjuvanted Arepanrix Group and the Flulaval/placebo/Arepanrix Group were pooled.

Posted

Number

Subjects

At Day 21 from Day 0 for the pooled group, Flulaval/unadjuvanted Arepanrix/placebo and Flulaval/Arepanrix/placebo Groups; at Day 63 from Day 42 for Unadjuvanted Arepanrix/placebo/Flulaval Group and Arepanrix/placebo/Flulaval Group

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001

Secondary

Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains

Seroprotection was defined as the proportion of subjects with H1N1 reciprocal Hemagglutination Inhibition (HI) titers ≥ 1:40 against the tested vaccine virus.

Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.

For the analysis the Flulaval/placebo/unadjuvanted Arepanrix Group and the Flulaval/placebo/Arepanrix Group were pooled.

Posted

Number

Subjects

At Day 21 for the pooled group, Flulaval/unadjuvanted Arepanrix/placebo and Flulaval/Arepanrix/placebo Groups; at Day 63 for Unadjuvanted Arepanrix/placebo/Flulaval Group and Arepanrix/placebo/Flulaval Group

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group

Secondary

Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.

Seroconversion factor was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal Hemagglutination Inhibition (HI) titer to the prevaccination reciprocal HI titer.

Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.

For the analysis the Flulaval/placebo/unadjuvanted Arepanrix Group and the Flulaval/placebo/Arepanrix Group were pooled.

Posted

Mean

95% Confidence Interval

Fold

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group

Secondary

Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains

Seroconversion defined as:

For initially seronegative subjects, antibody titer ≥ 1:40 after vaccination For initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer

Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.

Posted

Number

Subjects

on Days 21 and 63 from Day 0 for the first 4 groups; on Days 42 and 63 from Day 0 for the Unadjuvanted Arepanrix/placebo/Flulaval and Arepanrix/placebo/Flulaval Groups

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains

Seroconversion defined as:

For initially seronegative subjects, antibody titer ≥ 1:40 after vaccination For initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer

Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.

Posted

Number

Subjects

At Day 182 from Day 0

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.

Seroprotection rate was defined as the proportion of subjects with H1N1 reciprocal HI titers ≥ 40 against the tested vaccine virus.

Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.

Posted

Number

Subjects

before vaccination and on days 21 and 63 for the first 4 groups and before vaccination and on days 42 and 63 for the Unadjuvanted Arepanrix/placebo/Flulaval and Arepanrix/placebo/Flulaval Groups

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.

Seroprotection rate was defined as the proportion of subjects with H1N1 reciprocal HI titers ≥ 40 against the tested vaccine virus.

Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.

Posted

Number

Subjects

At Day 182 after the first dose

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.

Seroconversion factor of the within-subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer.

Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.

Posted

Mean

95% Confidence Interval

Fold

On Days 21 and 63 from Day 0 for the first 4 groups and on Days 42 and 63 from Day 0 for the Unadjuvanted Arepanrix/placebo/Flulaval and Arepanrix/placebo/Flulaval Groups

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.

Seroconversion factor of the within-subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer.

Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.

Posted

Mean

95% Confidence Interval

Fold

At Day 182 from Day 0

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.

Titers were expressed as geometric mean titers (GMTs).

Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.

Posted

Geometric Mean

95% Confidence Interval

Titers

On Days 0, 21 and 63 for the first 4 groups and on Days 0, 42 and 63 for the Unadjuvanted Arepanrix/placebo/Flulaval and Arepanrix/placebo/Flulaval Groups

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Secondary

Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.

Titers were expressed as geometric mean titers (GMTs).

Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.

Posted

Geometric Mean

95% Confidence Interval

Titers

At Day 182 after dose 1 vaccination

ID	Title	Description
OG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
OG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.

Arm/Groups

ID	Title	Description	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Flulaval/Placebo/Unadjuvanted Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.	3	102	92	102
EG001	Flulaval/Placebo/Arepanrix Group	subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.	1	104	91	104
EG002	Flulaval/Unadjuvanted Arepanrix/Placebo Group	subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.	1	102	86	102
EG003	Flulaval/Arepanrix/Placebo Group	subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.	2	100	97	100
EG004	Unadjuvanted Arepanrix/Placebo/Flulaval Group	subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.	1	101	84	101
EG005	Arepanrix/Placebo/Flulaval Group	subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.	3	102	99	102

Serious Adverse Events

Term	Organ System	Assessment Type	Statistical Information
Tenosynovitis	Musculoskeletal and connective tissue disorders	Non-systematic Assessment	EG0000 affected102 at risk EG0011 affected104 at risk EG0020 affected102 at risk EG0031 affected100 at risk EG0040 affected101 at risk EG0050 affected102 at risk
Abscess limb	Infections and infestations	Non-systematic Assessment	EG0000 affected102 at risk EG0011 affected104 at risk EG0020 affected102 at risk EG003
Alanine aminotransferase increased	Investigations	Non-systematic Assessment	EG0001 affected102 at risk EG0010 affected104 at risk EG0020 affected102 at risk EG003
Gestational hypertension	Pregnancy, puerperium and perinatal conditions	Non-systematic Assessment	EG0001 affected102 at risk EG0010 affected104 at risk EG0020 affected102 at risk EG003
Jaundice	Hepatobiliary disorders	Non-systematic Assessment	EG0001 affected102 at risk EG0010 affected104 at risk EG0020 affected102 at risk EG003
Oral disorder	Gastrointestinal disorders	Non-systematic Assessment	EG0000 affected102 at risk EG0010 affected104 at risk EG0020 affected102 at risk EG003
Pelvic fracture	Injury, poisoning and procedural complications	Non-systematic Assessment	EG0000 affected102 at risk EG0010 affected104 at risk EG0020 affected102 at risk EG003
Radius fracture	Injury, poisoning and procedural complications	Non-systematic Assessment	EG0000 affected102 at risk EG0010 affected104 at risk EG0020 affected102 at risk EG003
Scapula fracture	Injury, poisoning and procedural complications	Non-systematic Assessment	EG0000 affected102 at risk EG0010 affected104 at risk EG0020 affected102 at risk EG003
Seminoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Non-systematic Assessment	EG0000 affected102 at risk EG0010 affected104 at risk EG0020 affected102 at risk EG003
Sinus bradycardia	Cardiac disorders	Non-systematic Assessment	EG0001 affected102 at risk EG0010 affected104 at risk EG0020 affected102 at risk EG003
Suicide attempt	Psychiatric disorders	Non-systematic Assessment	EG0000 affected102 at risk EG0010 affected104 at risk EG0021 affected102 at risk EG003
VIIth nerve paralysis	Nervous system disorders	Non-systematic Assessment	EG0000 affected102 at risk EG0010 affected104 at risk EG0020 affected102 at risk EG003
Vomiting	Gastrointestinal disorders	Non-systematic Assessment	EG0001 affected102 at risk EG0010 affected104 at risk EG0020 affected102 at risk EG003

Other Adverse Events

Term	Organ System	Assessment Type	Statistical Information
Upper respiratory tract infection	Infections and infestations	Non-systematic Assessment	EG00011 affected102 at risk EG00111 affected104 at risk EG00211 affected102 at risk EG0038 affected100 at risk EG00415 affected101 at risk EG00511 affected102 at risk
Oropharyngeal pain	Respiratory, thoracic and mediastinal disorders	Non-systematic Assessment	EG00012 affected102 at risk EG00117 affected104 at risk EG0029 affected102 at risk EG003
Cough	Respiratory, thoracic and mediastinal disorders	Non-systematic Assessment	EG0009 affected102 at risk EG00111 affected104 at risk EG00211 affected102 at risk EG003
Nasal congestion	Respiratory, thoracic and mediastinal disorders	Non-systematic Assessment	EG0007 affected102 at risk EG0017 affected104 at risk EG0020 affected102 at risk EG003
Nasopharyngitis	Infections and infestations	Non-systematic Assessment	EG0000 affected102 at risk EG0010 affected104 at risk EG00210 affected102 at risk EG003
Nausea	Gastrointestinal disorders	Non-systematic Assessment	EG0009 affected102 at risk EG0018 affected104 at risk EG0020 affected102 at risk EG003
Dizziness	Nervous system disorders	Non-systematic Assessment	EG0000 affected102 at risk EG0017 affected104 at risk EG0020 affected102 at risk EG003
Headache	Nervous system disorders	Non-systematic Assessment	EG0000 affected102 at risk EG0010 affected104 at risk EG0020 affected102 at risk EG003
Rhinorrhoea	Respiratory, thoracic and mediastinal disorders	Non-systematic Assessment	EG0000 affected102 at risk EG0010 affected104 at risk EG0020 affected102 at risk EG003
Pain	General disorders	Systematic Assessment	EG00075 affected102 at risk EG00189 affected100 at risk EG00266 affected100 at risk EG003
Redness	General disorders	Systematic Assessment	EG0002 affected102 at risk EG0016 affected100 at risk EG0021 affected100 at risk EG003
Swelling	General disorders	Systematic Assessment	EG0002 affected102 at risk EG00115 affected100 at risk EG0022 affected100 at risk EG003
Fatigue	General disorders	Systematic Assessment	EG00054 affected102 at risk EG00162 affected100 at risk EG00241 affected100 at risk EG003
Headache	General disorders	Systematic Assessment	EG00052 affected102 at risk EG00158 affected100 at risk EG00251 affected100 at risk EG003
Joint pain at other location	General disorders	Systematic Assessment	EG00024 affected102 at risk EG00134 affected100 at risk EG00224 affected100 at risk EG003
Muscle aches	General disorders	Systematic Assessment	EG00038 affected102 at risk EG00152 affected100 at risk EG00239 affected100 at risk EG003
Shivering	General disorders	Systematic Assessment	EG00021 affected102 at risk EG00130 affected100 at risk EG00219 affected100 at risk EG003
Sweating	General disorders	Systematic Assessment	EG00022 affected102 at risk EG00121 affected100 at risk EG00221 affected100 at risk EG003
Temperature	General disorders	Systematic Assessment	EG0003 affected102 at risk EG0019 affected100 at risk EG0023 affected100 at risk EG003

Title

Denominators

Categories

A/Brisbane [D0] (N=25,25,24,25,25,26)

Title	Measurements
	OG0002533.40± 1225.90 OG0012604.64± 1435.48 OG0023521.33± 1922.24 OG0032612.56± 1256.47 OG0042644.40± 1219.04 OG0052016.31± 822.34

A/Brisbane [D7] (N=24,27,24,23,24,26)

Title	Measurements
	OG0004437.33± 1930.30 OG0014595.26± 2058.76 OG0025560.33± 3301.90 OG003

A/Brisbane [D21] (N=26,25,27,24,24,26)

Title	Measurements
	OG0003561.00± 1502.24 OG0013756.72± 1379.69 OG0025581.78± 3123.38 OG003

A/Brisbane [D28] (N=27,27,27,26,25,27)

Title	Measurements
	OG0003500.22± 1615.89 OG0014269.11± 1482.01 OG0025102.78± 2856.77 OG003

A/Brisbane [D42] (N=27,26,27,27,24,28)

Title	Measurements
	OG0003595.11± 1268.17 OG0015246.88± 2407.94 OG0024791.41± 2706.43 OG003

A/Brisbane [D63] (N=26,26,25,25,24,26)

Title	Measurements
	OG0003407.62± 1114.62 OG0016444.50± 2681.50 OG0024169.32± 2216.49 OG003

A/Brisbane [D182] (N=26,24,26,26,25,25)

Title	Measurements
	OG0003190.31± 1086.38 OG0014631.00± 1834.57 OG0024132.81± 1816.70 OG003

A/California [D0] (N=25,25,24,25,25,26)

Title	Measurements
	OG0002176.28± 1226.08 OG0011988.24± 1072.73 OG0022804.63± 1912.94 OG003

A/California [D7] (N=24,27,24,23,24,26)

Title	Measurements
	OG0004089.25± 2131.69 OG0013852.44± 1970.35 OG0024780.21± 2828.25 OG003

A/California [D21] (N=26,25,27,24,24,26)

Title	Measurements
	OG0003144.62± 1723.51 OG0013032.52± 1342.30 OG0024455.00± 2768.12 OG003

A/California [D28] (N=27,27,27,26,25,27)

Title	Measurements
	OG0003061.63± 1632.58 OG0013770.44± 1460.62 OG0024058.63± 2349.19 OG003

A/California [D42] (N=27,27,27,27,24,28)

Title	Measurements
	OG0002931.04± 1276.42 OG0014381.48± 2053.51 OG0023720.07± 2261.08 OG003

A/California [D63] (N=26,26,25,25,24,26)

Title	Measurements
	OG0002768.15± 1109.96 OG0015328.19± 2436.59 OG0023149.00± 1844.25 OG003

A/California [D182] (N=26,24,26,26,25,25)

Title	Measurements
	OG0001461.88± 735.77 OG0012333.88± 925.38 OG0021838.96± 842.26 OG003

Pool peptides H1 [D0] (N=25,24,24,25,23,25)

Title	Measurements
	OG000349.64± 336.13 OG001428.00± 296.76 OG002356.79± 206.44 OG003

Pool peptides H1 [D7] (N=24,27,24,23,24,25)

Title	Measurements
	OG000596.42± 500.15 OG001581.63± 527.07 OG002708.96± 518.87 OG003

Pool peptides H1 [D21] (N=26,24,27,24,24,26)

Title	Measurements
	OG000465.42± 352.18 OG001589.79± 459.57 OG002728.15± 623.89 OG003

Pool peptides H1 [D28] (N=26,27,27,26,25,27)

Title	Measurements
	OG000480.42± 392.81 OG001704.59± 518.63 OG002528.78± 322.10 OG003

Pool peptides H1 [D42] (N=27,27,27,27,24,28)

Title	Measurements
	OG000467.70± 302.91 OG0011049.96± 865.58 OG002514.78± 296.67 OG003

Pool peptides H1 [D63] (N=26,26,25,25,24,26)

Title	Measurements
	OG000504.92± 321.17 OG0011248.54± 1175.35 OG002460.28± 267.85 OG003

Pool peptides H1 [D182] (N=26,24,26,26,25,25)

Title	Measurements
	OG000554.65± 439.30 OG001824.17± 565.53 OG002531.73± 481.91 OG003

Pool Flu [D0] (N=24,25,24,25,25,24)

Title	Measurements
	OG0003286.63± 1710.00 OG0013531.36± 1972.37 OG0024315.71± 2499.77 OG003

Pool Flu [D7] (N=24,27,24,23,24,25)

Title	Measurements
	OG0006574.50± 3399.35 OG0016921.85± 4366.14 OG0027096.46± 3777.79 OG003

Pool Flu [D21] (N=25,25,27,24,24,25)

Title	Measurements
	OG0005234.16± 2513.78 OG0015124.60± 2268.53 OG0026579.26± 3489.20 OG003

Pool Flu [D28] (N=25,27,27,26,25,26)

Title	Measurements
	OG0004767.36± 2217.82 OG0015256.07± 2292.16 OG0026090.00± 3336.49 OG003

Pool Flu [D42] (N=26,27,27,26,24,27)

Title	Measurements
	OG0004734.42± 1823.28 OG0015881.78± 2641.14 OG0025721.70± 3058.63 OG003

Pool Flu [D63] (N=25,26,25,25,24,24)

Title	Measurements
	OG0004405.96± 1586.42 OG0016639.92± 3131.66 OG0024893.88± 2322.10 OG003

Pool Flu [D182] (N=26,24,26,26,25,25)

Title	Measurements
	OG0003304.50± 1393.44 OG0014325.63± 1541.34 OG0024006.46± 1836.30 OG003

Title

Denominators

Categories

A/Brisbane [D0] (N=25,25,24,25,25,26)

Title	Measurements
	OG000515.36± 1191.10 OG001382.84± 595.58 OG002489.08± 520.30 OG003183.96± 226.54 OG0041222.40± 4485.04 OG005119.46± 113.79

A/Brisbane [D7] (N=24,27,24,23,24,26)

Title	Measurements
	OG000772.96± 716.40 OG001884.81± 1225.90 OG0021115.96± 1545.07 OG003

A/Brisbane [D21] (N=26,25,27,24,24,26)

Title	Measurements
	OG000601.31± 1154.73 OG001517.44± 799.20 OG002655.22± 1327.00 OG003

A/Brisbane [D28] (N=27,27,27,26,25,27)

Title	Measurements
	OG000629.22± 964.11 OG001642.22± 850.79 OG002498.33± 730.34 OG003

A/Brisbane [D42] (N=27,26,27,27,24,28)

Title	Measurements
	OG000666.67± 1180.05 OG001551.88± 911.02 OG002525.07± 938.18 OG003

A/Brisbane [D63] (N=26,26,25,25,24,26)

Title	Measurements
	OG000620.00± 1393.77 OG001420.50± 486.62 OG002428.92± 687.17 OG003

A/Brisbane [D182] (N=26,24,26,26,25,25)

Title	Measurements
	OG000550.27± 1948.06 OG001436.79± 653.50 OG002377.65± 426.59 OG003

A/California [D0] (N=25,25,24,25,25,26)

Title	Measurements
	OG000357.40± 800.46 OG001189.28± 197.92 OG002271.58± 192.68 OG003

A/California [D7] (N=24,27,24,23,24,26)

Title	Measurements
	OG000610.29± 744.70 OG001466.93± 573.69 OG002716.88± 1251.20 OG003

A/California [D21] (N=26,25,27,24,24,26)

Title	Measurements
	OG000332.00± 539.48 OG001275.04± 334.83 OG002324.37± 668.77 OG003

A/California [D28] (N=27,27,27,26,25,27)

Title	Measurements
	OG000470.33± 655.02 OG001452.93± 547.61 OG002332.63± 553.07 OG003

A/California [D42] (N=27,27,27,27,24,28)

Title	Measurements
	OG000314.89± 289.95 OG001304.00± 255.38 OG002247.89± 459.58 OG003

A/California [D63] (N=26,2625,25,24,26)

Title	Measurements
	OG000203.62± 197.89 OG001260.54± 359.88 OG002242.36± 357.21 OG003

A/California [D182] (N=26,24,26,26,25,25)

Title	Measurements
	OG000214.85± 326.43 OG001220.71± 330.88 OG002225.50± 366.51 OG003

Pool peptides H1 [D0] (N=25,24,24,25,23,25)

Title	Measurements
	OG000110.48± 140.31 OG001180.38± 359.58 OG002101.04± 158.31 OG003

Pool peptides H1 [D7] (N=24,27,24,23,24,25)

Title	Measurements
	OG000205.33± 288.67 OG001185.15± 243.88 OG002202.13± 293.11 OG003

Pool peptides H1 [D21] (N=26,24,27,24,24,26)

Title	Measurements
	OG000103.81± 160.76 OG001194.92± 384.18 OG002101.30± 148.62 OG003

Pool peptides H1 [D28] (N=26,27,27,26,25,27)

Title	Measurements
	OG000100.08± 132.13 OG001170.04± 385.99 OG002124.56± 181.86 OG003

Pool peptides H1 [D42] (N=27,27,27,27,24,28)

Title	Measurements
	OG000143.67± 189.28 OG001157.41± 350.83 OG00287.41± 115.12 OG003

Pool peptides H1 [D63] (N=26,26,25,25,24,26)

Title	Measurements
	OG00085.96± 97.66 OG001173.88± 244.91 OG002113.20± 193.78 OG003

Pool peptides H1 [D182] (N=26,24,26,26,25,25)

Title	Measurements
	OG000287.31± 511.19 OG001265.63± 343.36 OG002306.04± 630.16 OG003

Pool Flu [D0] (N=24,25,24,25,25,24)

Title	Measurements
	OG000351.38± 467.93 OG001224.60± 251.59 OG002478.42± 463.43 OG003

Pool Flu [D7] (N=24,27,24,23,24,25)

Title	Measurements
	OG000986.92± 863.16 OG001843.44± 826.65 OG0021042.17± 1237.44 OG003

Pool Flu [D21] (N=25,25,27,24,24,25)

Title	Measurements
	OG000586.32± 876.08 OG001268.24± 324.48 OG002609.07± 997.10 OG003

Pool Flu [D28] (N=25,27,27,26,25,26)

Title	Measurements
	OG000484.48± 587.46 OG001508.11± 559.97 OG002505.33± 595.15 OG003

Pool Flu [D42] (N=26,27,27,26,24,27)

Title	Measurements
	OG000506.35± 560.83 OG001356.41± 392.23 OG002471.30± 610.38 OG003

Pool Flu [D63] (N=25,26,25,25,24,24)

Title	Measurements
	OG000461.20± 698.48 OG001325.12± 270.84 OG002402.24± 418.89 OG003

Pool Flu [D182] (N=26,24,26,26,25,25)

Title	Measurements
	OG000404.77± 981.01 OG001315.75± 441.50 OG002334.23± 447.12 OG003

Title

Denominators

Categories

ALAT [D0] Below (N=102,101,102,100,101,102)

Title	Measurements
	OG0000 OG0010 OG0020 OG0030 OG0040 OG0050

ALAT [D0] Within (N=102,101,102,100,101,102)

Title	Measurements
	OG000100 OG001101 OG00299 OG003

ALAT [D0] Above (N=102,101,102,100,101,102)

Title	Measurements
	OG0002 OG0013 OG0022 OG003

ALAT [D7] Below (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

ALAT [D7] Within (N=102,101,100,99,100,99)

Title	Measurements
	OG000100 OG00196 OG00299 OG003

ALAT [D7] Above (N=102,101,100,99,100,99)

Title	Measurements
	OG0002 OG0015 OG0021 OG003

ALAT [D21] Below (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

ALAT [D21] Within (N=101,100,97,97,99,99)

Title	Measurements
	OG00096 OG00197 OG00296 OG003

ALAT [D21] Above (N=101,100,97,97,99,99)

Title	Measurements
	OG0005 OG0013 OG0021 OG003

ALAT [D28] Below (N=101,98,96,98,98,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

ALAT [D28] Within (N=101,98,96,98,98,97)

Title	Measurements
	OG00096 OG00196 OG00294 OG003

ALAT [D28] Above (N=101,98,96,98,98,97)

Title	Measurements
	OG0004 OG0012 OG0022 OG003

ALAT [D42] Below (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

ALAT [D42] Within (N=101,97,95,95,96,97)

Title	Measurements
	OG00097 OG00194 OG00293 OG003

ALAT [D42] Above (N=101,97,95,95,96,97)

Title	Measurements
	OG0004 OG0013 OG0021 OG003

ALAT [D63] Below (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

ALAT [D63] Within (N=100,95,95,95,97,97)

Title	Measurements
	OG00093 OG00189 OG00293 OG003

ALAT [D63] Above (N=100,95,95,95,97,97)

Title	Measurements
	OG0006 OG0015 OG0021 OG003

ALAT [D182] Below (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

ALAT [D182] Within (N=99,91,88,91,93,97)

Title	Measurements
	OG00097 OG00189 OG00288 OG003

ALAT [D182] Above (N=99,91,88,91,93,97)

Title	Measurements
	OG0002 OG0011 OG0020 OG003

AP [D0] Below (N=102,104, 102,100,101,102)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

AP [D0] Within (N=102,104, 102,100,101,102)

Title	Measurements
	OG000102 OG001104 OG002100 OG003

AP [D0] Above (N=102,104, 102,100,101,102)

Title	Measurements
	OG0000 OG0010 OG0021 OG003

AP [D7] Below (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

AP [D7] Within (N=102,101,100,99,100,99)

Title	Measurements
	OG000101 OG001101 OG002100 OG003

AP [D7] Above (N=102,101,100,99,100,99)

Title	Measurements
	OG0001 OG0010 OG0020 OG003

AP [D21] Below (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

AP [D21] Within (N=101,100,97,97,99,99)

Title	Measurements
	OG000101 OG001100 OG00296 OG003

AP [D21] Above (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0010 OG0021 OG003

AP [D28] Below (N=101,98,96,98,98,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

AP [D28] Within (N=101,98,96,98,98,97)

Title	Measurements
	OG00099 OG00197 OG00295 OG003

AP [D28] Above (N=101,98,96,98,98,97)

Title	Measurements
	OG0001 OG0011 OG0021 OG003

AP [D42] Below (N=101,97, 95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

AP [D42] Within (N=101,97, 95,95,96,97)

Title	Measurements
	OG00099 OG00197 OG00294 OG003

AP [D42] Above (N=101,97, 95,95,96,97)

Title	Measurements
	OG0002 OG0010 OG0020 OG003

AP [D63] Below (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

AP [D63] Within (N=100,95,95,95,97,97)

Title	Measurements
	OG00099 OG00194 OG00293 OG003

AP [D63] Above (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0010 OG0021 OG003

AP [D182] Below (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

AP [D182] Within (N=99,91,88,91,93,97)

Title	Measurements
	OG00098 OG00190 OG00288 OG003

AP [D182] Above (N=99,91,88,91,93,97)

Title	Measurements
	OG0001 OG0010 OG0020 OG003

ASAT [D0] Below (N=102,104,102,100,101,102)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

ASAT [D0] Within (N=102,104,102,100,101,102)

Title	Measurements
	OG000101 OG001102 OG002100 OG003

ASAT [D0] Above (N=102,104,102,100,101,102)

Title	Measurements
	OG0001 OG0012 OG0021 OG003

ASAT [D7] Below (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

ASAT [D7] Within (N=102,101,100,99,100,99)

Title	Measurements
	OG00099 OG00199 OG00297 OG003

ASAT [D7] Above (N=102,101,100,99,100,99)

Title	Measurements
	OG0003 OG0012 OG0022 OG003

ASAT [D21] Below (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

ASAT [D21] Within (N=101,100,97,97,99,99)

Title	Measurements
	OG00099 OG00199 OG00297 OG003

ASAT [D21] Above (N=101,100,97,97,99,99)

Title	Measurements
	OG0002 OG0011 OG0020 OG003

ASAT [D28] Below (N=101,98,96,98,98,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

ASAT [D28] Within (N=101,98,96,98,98,97)

Title	Measurements
	OG00096 OG00197 OG00293 OG003

ASAT [D28] Above (N=101,98,96,98,98,97)

Title	Measurements
	OG0004 OG0011 OG0023 OG003

ASAT [D42] Below (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

ASAT [D42] Within (N=101,97,95,95,96,97)

Title	Measurements
	OG00095 OG00195 OG00293 OG003

ASAT [D42] Above (N=101,97,95,95,96,97)

Title	Measurements
	OG0006 OG0012 OG0021 OG003

ASAT [D63] Below (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

ASAT [D63] Within (N=100,95,95,95,97,97)

Title	Measurements
	OG00098 OG00194 OG00292 OG003

ASAT [D63] Above (N=100,95,95,95,97,97)

Title	Measurements
	OG0001 OG0010 OG0021 OG003

ASAT [D182] Below (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

ASAT [D182] Within (N=99,91,88,91,93,97)

Title	Measurements
	OG00096 OG00186 OG00287 OG003

ASAT [D182] Above (N=99,91,88,91,93,97)

Title	Measurements
	OG0002 OG0014 OG0020 OG003

BAS [D0] Below (N=102,104,102,100,101,102)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BAS [D0] Within (N=102,104,102,100,101,102)

Title	Measurements
	OG000100 OG001104 OG002102 OG003

BAS [D0] Above (N=102,104,102,100,101,102)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BAS [D7] Below (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BAS [D7] Within (N=102,101,100,99,100,99)

Title	Measurements
	OG000102 OG001100 OG002100 OG003

BAS [D7] Above (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BAS [D21] Below (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BAS [D21] Within (N=101,100,97,97,99,99)

Title	Measurements
	OG000101 OG00199 OG00294 OG003

BAS [D21] Above (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BAS [D28] Below (N=101,98,96,98,98,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BAS [D28] Within (N=101,98,96,98,98,97)

Title	Measurements
	OG00099 OG00196 OG00296 OG003

BAS [D28] Above (N=101,98,96,98,98,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BAS [D42] Below (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BAS [D42] Within (N=101,97,95,95,96,97)

Title	Measurements
	OG000101 OG00197 OG00295 OG003

BAS [D42] Above (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BAS [D63] Below (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BAS [D63] Within (N=100,95,95,95,97,97)

Title	Measurements
	OG000100 OG00195 OG00295 OG003

BAS [D63] Above (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BAS [D182] Below (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BAS [D182] Within (N=99,91,88,91,93,97)

Title	Measurements
	OG00099 OG00191 OG00288 OG003

BAS [D182] Above (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BIL T [D0] Below (N=102,104,102,100,101,102)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BIL T [D0] Within (N=102,104,102,100,101,102)

Title	Measurements
	OG000101 OG001102 OG002100 OG003

BIL T [D0] Above (N=102,104,102,100,101,102)

Title	Measurements
	OG0001 OG0012 OG0021 OG003

BIL T [D7] Below (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BIL T [D7] Within (N=102,101,100,99,100,99)

Title	Measurements
	OG000101 OG001100 OG00297 OG003

BIL T [D7] Above (N=102,101,100,99,100,99)

Title	Measurements
	OG0001 OG0011 OG0023 OG003

BIL T [D21] Below (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BIL T [D21] Within (N=101,100,97,97,99,99)

Title	Measurements
	OG00099 OG00197 OG00295 OG003

BIL T [D21] Above (N=101,100,97,97,99,99)

Title	Measurements
	OG0002 OG0013 OG0022 OG003

BIL T [D28] Below (N=101,98,96,98,98,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BIL T [D28] Within (N=101,98,96,98,98,97)

Title	Measurements
	OG00099 OG00196 OG00294 OG003

BIL T [D28] Above (N=101,98,96,98,98,97)

Title	Measurements
	OG0001 OG0012 OG0022 OG003

BIL T [D42] Below (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BIL T [D42] Within (N=101,97,95,95,96,97)

Title	Measurements
	OG00098 OG00193 OG00292 OG003

BIL T [D42] Above (N=101,97,95,95,96,97)

Title	Measurements
	OG0003 OG0014 OG0022 OG003

BIL T [D63] Below (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BIL T [D63] Within (N=100,95,95,95,97,97)

Title	Measurements
	OG00098 OG00192 OG00292 OG003

BIL T [D63] Above (N=100,95,95,95,97,97)

Title	Measurements
	OG0001 OG0012 OG0022 OG003

BIL T [D182] Below (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BIL T [D182] Within (N=99,91,88,91,93,97)

Title	Measurements
	OG00099 OG00187 OG00286 OG003

BIL T [D182] Above (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0013 OG0022 OG003

ALAT [D0] Unknown (N=102,101,102,100,101,102)

Title	Measurements
	OG0000 OG0010 OG0021 OG003

ALAT [D7] Unknown (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

ALAT [D21] Unknown (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

ALAT [D28] Unknown (N=101,98,96,98,98,97)

Title	Measurements
	OG0001 OG0010 OG0020 OG003

ALAT [D42] Unknown (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0021 OG003

ALAT [D63] Unknown (N=100,95,95,95,97,97)

Title	Measurements
	OG0001 OG0011 OG0021 OG003

ALAT [D182] Unknown (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0011 OG0020 OG003

AP [D0] Unknown (N=102,104, 102,100,101,102)

Title	Measurements
	OG0000 OG0010 OG0021 OG003

AP [D7] Unknown (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

AP [D21] Unknown (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

AP [D28] Unknown (N=101,98,96,98,98,97)

Title	Measurements
	OG0001 OG0010 OG0020 OG003

AP [D42] Unknown (N=101,97, 95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0021 OG003

AP [D63] Unknown (N=100,95,95,95,97,97)

Title	Measurements
	OG0001 OG0011 OG0021 OG003

AP [D182] Unknown (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0011 OG0020 OG003

ASAT [D0] Unknown (N=102,104,102,100,101,102)

Title	Measurements
	OG0000 OG0010 OG0021 OG003

ASAT [D7] Unknown (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0010 OG0021 OG003

ASAT [D21] Unknown (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

ASAT [D28] Unknown (N=101,98,96,98,98,97)

Title	Measurements
	OG0001 OG0010 OG0020 OG003

ASAT [D42] Unknown (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0021 OG003

ASAT [D63] Unknown (N=100,95,95,95,97,97)

Title	Measurements
	OG0001 OG0011 OG0022 OG003

ASAT [D182] Unknown (N=99,91,88,91,93,97)

Title	Measurements
	OG0001 OG0011 OG0021 OG003

BAS [D0] Unknown (N=102,104,102,100,101,102)

Title	Measurements
	OG0002 OG0010 OG0020 OG003

BAS [D7] Unknown (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0011 OG0020 OG003

BAS [D21] Unknown (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0011 OG0023 OG003

BAS [D28] Unknown (N=101,98,96,98,98,97)

Title	Measurements
	OG0002 OG0012 OG0020 OG003

BAS [D42] Unknown (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BAS [D63] Unknown (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BAS [D182] Unknown (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BIL T [D0] Unknown (N=102,104,102,100,101,102)

Title	Measurements
	OG0000 OG0010 OG0021 OG003

BIL T [D7] Unknown (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BIL T [D21] Unknown (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BIL T [D28] Unknown (N=101,98,96,98,98,97)

Title	Measurements
	OG0001 OG0010 OG0020 OG003

BIL T [D42] Unknown (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0021 OG003

BIL T [D63] Unknown (N=100,95,95,95,97,97)

Title	Measurements
	OG0001 OG0011 OG0021 OG003

BIL T [D182] Unknown (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0011 OG0020 OG003

Title

Denominators

Categories

BIL D [D0] Below (N=102,104,102,100,101,102)

Title	Measurements
	OG0000 OG0010 OG0020 OG0030 OG0040 OG0050

BIL D [D0] Within (N=102,104,102,100,101,102)

Title	Measurements
	OG000101 OG001104 OG002101 OG003

BIL D [D0] Above (N=102,104,102,100,101,102)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BIL D [D0] Unknown (N=102,104,102,100,101,102)

Title	Measurements
	OG0001 OG0010 OG0021 OG003

BIL D [D7] Below (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BIL D [D7] Within (N=102,101,100,99,100,99)

Title	Measurements
	OG000102 OG001101 OG002100 OG003

BIL D [D7] Above (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BIL D [D7] Unknown(N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BIL D [D21] Below (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BIL D [D21] Within (N=101,100,97,97,99,99)

Title	Measurements
	OG000101 OG001100 OG00297 OG003

BIL D [D21] Above (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BIL D [D21] Unknown (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BIL D [D28] Below (N=101,98,96,98,98,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BIL D [D28] Within (N=101,98,96,98,98,97)

Title	Measurements
	OG000100 OG00198 OG00296 OG003

BIL D [D28] Above (N=101,98,96,98,98,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BIL D [D28] Unknown (N=101,98,96,98,98,97)

Title	Measurements
	OG0001 OG0010 OG0020 OG003

BIL D [D42] Below (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BIL D [D42] Within (N=101,97,95,95,96,97)

Title	Measurements
	OG000101 OG00197 OG00294 OG003

BIL D [D42] Above (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BIL D [D42] Unknown (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0021 OG003

BIL D [D63] Below (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BIL D [D63] Within (N=100,95,95,95,97,97)

Title	Measurements
	OG00099 OG00194 OG00294 OG003

BIL D [D63] Above (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BIL D [D63] Unknown (N=100,95,95,95,97,97)

Title	Measurements
	OG0001 OG0011 OG0021 OG003

BIL D [D182] Below (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BIL D [D182] Within (N=99,91,88,91,93,97)

Title	Measurements
	OG00099 OG00190 OG00288 OG003

BIL D [D182] Above (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

BIL D [D182] Unknown (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0011 OG0020 OG003

CREA [D0] Below (N=102,104,102,100,101,102)

Title	Measurements
	OG0008 OG0016 OG0026 OG003

CREA [D0] Within (N=102,104,102,100,101,102)

Title	Measurements
	OG00093 OG00197 OG00294 OG003

CREA [D0] Above (N=102,104,102,100,101,102)

Title	Measurements
	OG0001 OG0011 OG0021 OG003

CREA [D0] Unknown (N=102,104,102,100,101,102)

Title	Measurements
	OG0000 OG0010 OG0021 OG003

CREA [D7] Below (N=102,101,100,99,100,99)

Title	Measurements
	OG0008 OG0016 OG0029 OG003

CREA [D7] Within (N=102,101,100,99,100,99)

Title	Measurements
	OG00094 OG00193 OG00291 OG003

CREA [D7] Above (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0012 OG0020 OG003

CREA [D7] Unknown (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

CREA [D21] Below (N=101,100,97,97,99,99)

Title	Measurements
	OG00012 OG0016 OG0025 OG003

CREA [D21] Within (N=101,100,97,97,99,99)

Title	Measurements
	OG00088 OG00192 OG00292 OG003

CREA [D21] Above (N=101,100,97,97,99,99)

Title	Measurements
	OG0001 OG0012 OG0020 OG003

CREA [D21] Unknown (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

CREA [D28] Below (N=101,98,96,98,98,97)

Title	Measurements
	OG0005 OG0018 OG0026 OG003

CREA [D28] Within (N=101,98,96,98,98,97)

Title	Measurements
	OG00095 OG00190 OG00289 OG003

CREA [D28] Above (N=101,98,96,98,98,97)

Title	Measurements
	OG0000 OG0010 OG0021 OG003

CREA [D28] Unknown (N=101,98,96,98,98,97)

Title	Measurements
	OG0001 OG0010 OG0020 OG003

CREA [D42] Below (N=101,97,95,95,96,97)

Title	Measurements
	OG0006 OG0015 OG0025 OG003

CREA [D42] Within (N=101,97,95,95,96,97)

Title	Measurements
	OG00095 OG00190 OG00288 OG003

CREA [D42] Above (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0012 OG0021 OG003

CREA [D42] Unknown (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0021 OG003

CREA [D63] Below (N=100,95,95,95,97,97)

Title	Measurements
	OG0007 OG0017 OG0027 OG003

CREA [D63] Within (N=100,95,95,95,97,97)

Title	Measurements
	OG00092 OG00186 OG00287 OG003

CREA [D63] Above (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0011 OG0020 OG003

CREA [D63] Unknown (N=100,95,95,95,97,97)

Title	Measurements
	OG0001 OG0011 OG0021 OG003

CREA [D182] Below (N=99,91,88,91,93,97)

Title	Measurements
	OG00014 OG0017 OG0027 OG003

CREA [D182] Within (N=99,91,88,91,93,97)

Title	Measurements
	OG00084 OG00182 OG00280 OG003

CREA [D182] Above (N=99,91,88,91,93,97)

Title	Measurements
	OG0001 OG0011 OG0021 OG003

CREA [D182] Unknown (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0011 OG0020 OG003

EOS [D0] Below (N=102,104,102,100,101,102)

Title	Measurements
	OG0002 OG0016 OG0027 OG003

EOS [D0] Within (N=102,104,102,100,101,102)

Title	Measurements
	OG00097 OG00196 OG00293 OG003

EOS [D0] Above (N=102,104,102,100,101,102)

Title	Measurements
	OG0001 OG0012 OG0022 OG003

EOS [D0] Unknown (N=102,104,102,100,101,102)

Title	Measurements
	OG0002 OG0010 OG0020 OG003

EOS [D7] Below (N=102,101,100,99,100,99)

Title	Measurements
	OG0007 OG0014 OG0027 OG003

EOS [D7] Within (N=102,101,100,99,100,99)

Title	Measurements
	OG00093 OG00193 OG00291 OG003

EOS [D7] Above (N=102,101,100,99,100,99)

Title	Measurements
	OG0002 OG0013 OG0022 OG003

EOS [D7] Unknown (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0011 OG0020 OG003

EOS [D21] Below (N=101,100,97,97,99,99)

Title	Measurements
	OG0002 OG0018 OG0029 OG003

EOS [D21] Within (N=101,100,97,97,99,99)

Title	Measurements
	OG00097 OG00187 OG00285 OG003

EOS [D21] Above (N=101,100,97,97,99,99)

Title	Measurements
	OG0002 OG0014 OG0020 OG003

EOS [D21] Unknown (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0011 OG0023 OG003

EOS [D28] Below (N=101,98,96,98,98,97)

Title	Measurements
	OG0004 OG0014 OG0027 OG003

EOS [D28] Within (N=101,98,96,98,98,97)

Title	Measurements
	OG00094 OG00190 OG00289 OG003

EOS [D28] Above (N=101,98,96,98,98,97)

Title	Measurements
	OG0001 OG0012 OG0020 OG003

EOS [D28] Unknown (N=101,98,96,98,98,97)

Title	Measurements
	OG0002 OG0012 OG0020 OG003

EOS [D42] Below (N=101,97,95,95,96,97)

Title	Measurements
	OG0004 OG0019 OG0026 OG003

EOS [D42] Within (N=101,97,95,95,96,97)

Title	Measurements
	OG00096 OG00186 OG00289 OG003

EOS [D42] Above (N=101,97,95,95,96,97)

Title	Measurements
	OG0001 OG0012 OG0020 OG003

EOS [D42] Unknown (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

EOS [D63] Below (N=100,95,95,95,97,97)

Title	Measurements
	OG0002 OG0019 OG0028 OG003

EOS [D63] Within (N=100,95,95,95,97,97)

Title	Measurements
	OG00097 OG00182 OG00285 OG003

EOS [D63] Above (N=100,95,95,95,97,97)

Title	Measurements
	OG0001 OG0014 OG0022 OG003

EOS [D63] Unknown (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

EOS [D182] Below (N=99,91,88,91,93,97)

Title	Measurements
	OG0003 OG0014 OG0029 OG003

EOS [D182] Within (N=99,91,88,91,93,97)

Title	Measurements
	OG00094 OG00186 OG00278 OG003

EOS [D182] Above (N=99,91,88,91,93,97)

Title	Measurements
	OG0002 OG0011 OG0021 OG003

EOS [D182] Unknown (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

Hct [D0] Below (N=102,104,102,100,101,102)

Title	Measurements
	OG0004 OG0012 OG0024 OG003

Hct [D0] Within (N=102,104,102,100,101,102)

Title	Measurements
	OG00094 OG00199 OG00295 OG003

Hct [D0] Above (N=102,104,102,100,101,102)

Title	Measurements
	OG0002 OG0013 OG0023 OG003

Hct [D0] Unknown (N=102,104,102,100,101,102)

Title	Measurements
	OG0002 OG0010 OG0020 OG003

Hct [D7] Below (N=102,101,100,99,100,99)

Title	Measurements
	OG0007 OG0017 OG0024 OG003

Hct [D7] Within (N=102,101,100,99,100,99)

Title	Measurements
	OG00093 OG00191 OG00295 OG003

Hct [D7] Above (N=102,101,100,99,100,99)

Title	Measurements
	OG0002 OG0012 OG0021 OG003

Hct [D7] Unknown (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0011 OG0020 OG003

Hct [D21] Below (N=101,100,97,97,99,99)

Title	Measurements
	OG0008 OG0014 OG0025 OG003

Hct [D21] Within (N=101,100,97,97,99,99)

Title	Measurements
	OG00092 OG00194 OG00288 OG003

Hct [D21] Above (N=101,100,97,97,99,99)

Title	Measurements
	OG0001 OG0011 OG0021 OG003

Hct [D21] Unknown (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0011 OG0023 OG003

Hct [D28] Below (N=101,98,96,98,98,97)

Title	Measurements
	OG00010 OG0016 OG0028 OG003

Hct [D28] Within (N=101,98,96,98,98,97)

Title	Measurements
	OG00089 OG00188 OG00286 OG003

Hct [D28] Above (N=101,98,96,98,98,97)

Title	Measurements
	OG0001 OG0012 OG0022 OG003

Hct [D28] Unknown (N=101,98,96,98,98,97)

Title	Measurements
	OG0001 OG0012 OG0020 OG003

Hct [D42] Below (N=101,97,95,95,96,97)

Title	Measurements
	OG00011 OG0019 OG0029 OG003

Hct [D42] Within (N=101,97,95,95,96,97)

Title	Measurements
	OG00090 OG00186 OG00286 OG003

Hct [D42] Above (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0012 OG0020 OG003

Hct [D42] Unknown (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

Hct [D63] Below (N=100,95,95,95,97,97)

Title	Measurements
	OG0008 OG00110 OG00211 OG003

Hct [D63] Within (N=100,95,95,95,97,97)

Title	Measurements
	OG00092 OG00184 OG00284 OG003

Hct [D63] Above (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0011 OG0020 OG003

Hct [D63] Unknown (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

Hct [D182] Below (N=99,91,88,91,93,97)

Title	Measurements
	OG0004 OG0016 OG0024 OG003

Hct [D182] Within (N=99,91,88,91,93,97)

Title	Measurements
	OG00093 OG00184 OG00282 OG003

Hct [D182] Above (N=99,91,88,91,93,97)

Title	Measurements
	OG0002 OG0011 OG0022 OG003

Hct [D182] Unknown (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

Hgb [D0] Below (N=102,104,102,100,101,102)

Title	Measurements
	OG0002 OG0016 OG0025 OG003

Hgb [D0] Within (N=102,104,102,100,101,102)

Title	Measurements
	OG00097 OG00197 OG00295 OG003

Hgb [D0] Above (N=102,104,102,100,101,102)

Title	Measurements
	OG0001 OG0011 OG0022 OG003

Hgb [D0] Unknown (N=102,104,102,100,101,102)

Title	Measurements
	OG0002 OG0010 OG0020 OG003

Hgb [D7] Below (N=102,101,100,99,100,99)

Title	Measurements
	OG0006 OG0017 OG0025 OG003

Hgb [D7] Within (N=102,101,100,99,100,99)

Title	Measurements
	OG00094 OG00191 OG00294 OG003

Hgb [D7] Above (N=102,101,100,99,100,99)

Title	Measurements
	OG0002 OG0012 OG0021 OG003

Hgb [D7] Unknown (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0011 OG0020 OG003

Hgb [D21] Below (N=101,100,97,97,99,99)

Title	Measurements
	OG0006 OG0015 OG0023 OG003

Hgb [D21] Within (N=101,100,97,97,99,99)

Title	Measurements
	OG00093 OG00194 OG00290 OG003

Hgb [D21] Above (N=101,100,97,97,99,99)

Title	Measurements
	OG0002 OG0010 OG0021 OG003

Hgb [D21] Unknown (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0011 OG0023 OG003

Hgb [D28] Below (N=101,98,96,98,98,97)

Title	Measurements
	OG00010 OG0017 OG0025 OG003

Hgb [D28] Within (N=101,98,96,98,98,97)

Title	Measurements
	OG00090 OG00188 OG00289 OG003

Hgb [D28] Above (N=101,98,96,98,98,97)

Title	Measurements
	OG0000 OG0011 OG0022 OG003

Hgb [D28] Unknown (N=101,98,96,98,98,97)

Title	Measurements
	OG0001 OG0012 OG0020 OG003

Hgb [D42] Below (N=101,97,95,95,96,97)

Title	Measurements
	OG0007 OG0018 OG0026 OG003

Hgb [D42] Within (N=101,97,95,95,96,97)

Title	Measurements
	OG00094 OG00187 OG00289 OG003

Hgb [D42] Above (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0012 OG0020 OG003

Hgb [D42] Unknown (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

Hgb [D63] Below (N=100,95,95,95,97,97)

Title	Measurements
	OG0008 OG00110 OG0026 OG003

Hgb [D63] Within (N=100,95,95,95,97,97)

Title	Measurements
	OG00092 OG00183 OG00289 OG003

Hgb [D63] Above (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0012 OG0020 OG003

Hgb [D63] Unknown (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

Hgb [D182] Below (N=99,91,88,91,93,97)

Title	Measurements
	OG0009 OG0016 OG0025 OG003

Hgb [D182] Within (N=99,91,88,91,93,97)

Title	Measurements
	OG00089 OG00184 OG00281 OG003

Hgb [D182] Above (N=99,91,88,91,93,97)

Title	Measurements
	OG0001 OG0011 OG0022 OG003

Hgb [D182] Unknown (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

Title

Denominators

Categories

Fatigue

Title	Measurements
	OG00054 OG00162 OG00241 OG00358 OG00457 OG00556

Headache

Title	Measurements
	OG00052 OG00158 OG00251 OG003

Joint pain at other location

Title	Measurements
	OG00024 OG00134 OG00224 OG003

Muscle aches

Title	Measurements
	OG00038 OG00152 OG00239 OG003

Shivering

Title	Measurements
	OG00021 OG00130 OG00219 OG003

Sweating

Title	Measurements
	OG00022 OG00121 OG00221 OG003

Temperature (axillary) >=38°C

Title	Measurements
	OG0003 OG0019 OG0023 OG003

Title

Denominators

Categories

RBC [D0] Below (N=102,104,102,100101,102)

Title	Measurements
	OG0004 OG0012 OG0027 OG0033 OG0042 OG0054

RBC [D0] Within (N=102,104,102,100101,102)

Title	Measurements
	OG00096 OG001100 OG00295 OG003

RBC [D0] Above (N=102,104,102,100101,102)

Title	Measurements
	OG0000 OG0012 OG0020 OG003

RBC [D0] Unknown (N=102,104,102,100101,102)

Title	Measurements
	OG0002 OG0010 OG0020 OG003

RBC [D7] Below (N=102,101,100,99,100,99)

Title	Measurements
	OG0003 OG0015 OG0025 OG003

RBC [D7] Within (N=102,101,100,99,100,99)

Title	Measurements
	OG00099 OG00194 OG00295 OG003

RBC [D7] Above (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0011 OG0020 OG003

RBC [D7] Unknown (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0011 OG0020 OG003

RBC [D21] Below (N=101,100,97,97,99,99)

Title	Measurements
	OG0005 OG0017 OG0025 OG003

RBC [D21] Within (N=101,100,97,97,99,99)

Title	Measurements
	OG00096 OG00192 OG00289 OG003

RBC [D21] Above (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

RBC [D21] Unknown (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0011 OG0023 OG003

RBC [D28] Below (N=101,98,96,98,98,97)

Title	Measurements
	OG0005 OG0018 OG0028 OG003

RBC [D28] Within (N=101,98,96,98,98,97)

Title	Measurements
	OG00095 OG00187 OG00288 OG003

RBC [D28] Above (N=101,98,96,98,98,97)

Title	Measurements
	OG0000 OG0011 OG0020 OG003

RBC [D28] Unknown (N=101,98,96,98,98,97)

Title	Measurements
	OG0001 OG0012 OG0020 OG003

RBC [D42] Below (N=101,97,95,95,96,97)

Title	Measurements
	OG0002 OG0019 OG0029 OG003

RBC [D42] Within (N=101,97,95,95,96,97)

Title	Measurements
	OG00099 OG00187 OG00286 OG003

RBC [D42] Above (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0011 OG0020 OG003

RBC [D42] Unknown (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

RBC [D63] Below (N=100,95,95,95,97,97)

Title	Measurements
	OG0006 OG0018 OG0025 OG003

RBC [D63] Within (N=100,95,95,95,97,97)

Title	Measurements
	OG00094 OG00186 OG00290 OG003

RBC [D63] Above (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0011 OG0020 OG003

RBC [D63] Unknown (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

RBC [D182] Below (N=99,91,88,91,93,97)

Title	Measurements
	OG0006 OG0016 OG0029 OG003

RBC [D182] Within (N=99,91,88,91,93,97)

Title	Measurements
	OG00092 OG00185 OG00277 OG003

RBC [D182] Above (N=99,91,88,91,93,97)

Title	Measurements
	OG0001 OG0010 OG0022 OG003

RBC [D182] Unknown (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

SUN [D0] Below (N=102,104,102,100101,102)

Title	Measurements
	OG0001 OG0010 OG0021 OG003

SUN [D0] Within (N=102,104,102,100101,102)

Title	Measurements
	OG000100 OG001104 OG002100 OG003

SUN [D0] Above (N=102,104,102,100101,102)

Title	Measurements
	OG0001 OG0010 OG0020 OG003

SUN [D0] Unknown (N=102,104,102,100101,102)

Title	Measurements
	OG0000 OG0010 OG0021 OG003

SUN [D7] Below (N=102,101,100,99,100,99)

Title	Measurements
	OG0002 OG0011 OG0024 OG003

SUN [D7] Within (N=102,101,100,99,100,99)

Title	Measurements
	OG000100 OG00199 OG00296 OG003

SUN [D7] Above (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0011 OG0020 OG003

SUN [D7] Unknown (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

SUN [D21] Below (N=101,100,97,97,99,99)

Title	Measurements
	OG0001 OG0011 OG0020 OG003

SUN [D21] Within (N=101,100,97,97,99,99)

Title	Measurements
	OG000100 OG00199 OG00296 OG003

SUN [D21] Above (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0010 OG0021 OG003

SUN [D21] Unknown (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

SUN [D28] Below (N=101,98,96,98,98,97)

Title	Measurements
	OG0002 OG0011 OG0020 OG003

SUN [D28] Within (N=101,98,96,98,98,97)

Title	Measurements
	OG00098 OG00197 OG00296 OG003

SUN [D28] Above (N=101,98,96,98,98,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

SUN [D28] Unknown (N=101,98,96,98,98,97)

Title	Measurements
	OG0001 OG0010 OG0020 OG003

SUN [D42] Below (N=101,97,95,95,96,97)

Title	Measurements
	OG0001 OG0011 OG0022 OG003

SUN [D42] Within (N=101,97,95,95,96,97)

Title	Measurements
	OG000100 OG00196 OG00291 OG003

SUN [D42] Above (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0021 OG003

SUN [D42] Unknown (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0021 OG003

SUN [D63] Below (N=100,95,95,95,97,97)

Title	Measurements
	OG0001 OG0010 OG0021 OG003

SUN [D63] Within (N=100,95,95,95,97,97)

Title	Measurements
	OG00098 OG00194 OG00293 OG003

SUN [D63] Above (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

SUN [D63] Unknown (N=100,95,95,95,97,97)

Title	Measurements
	OG0001 OG0011 OG0021 OG003

SUN [D182] Below (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0012 OG0021 OG003

SUN [D182] Within (N=99,91,88,91,93,97)

Title	Measurements
	OG00099 OG00188 OG00287 OG003

SUN [D182] Above (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

SUN [D182] Unknown (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0011 OG0020 OG003

WBC [D0] Below (N=102,104,102,100,101,102)

Title	Measurements
	OG0001 OG0012 OG0025 OG003

WBC [D0] Within (N=102,104,102,100,101,102)

Title	Measurements
	OG00095 OG001100 OG00294 OG003

WBC [D0] Above (N=102,104,102,100,101,102)

Title	Measurements
	OG0004 OG0012 OG0023 OG003

WBC [D0] Unknown (N=102,104,102,100,101,102)

Title	Measurements
	OG0002 OG0010 OG0020 OG003

WBC [D7] Below (N=102,101,100,99,100,99)

Title	Measurements
	OG0003 OG0010 OG0022 OG003

WBC [D7] Within (N=102,101,100,99,100,99)

Title	Measurements
	OG00099 OG00197 OG00298 OG003

WBC [D7] Above (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0013 OG0020 OG003

WBC [D7] Unknown (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0011 OG0020 OG003

WBC [D21] Below (N=101,100,97,97,99,99)

Title	Measurements
	OG0001 OG0014 OG0022 OG003

WBC [D21] Within (N=101,100,97,97,99,99)

Title	Measurements
	OG00098 OG00194 OG00290 OG003

WBC [D21] Above (N=101,100,97,97,99,99)

Title	Measurements
	OG0002 OG0011 OG0022 OG003

WBC [D21] Unknown (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0011 OG0023 OG003

WBC [D28] Below (N=101,98,96,98,98,97)

Title	Measurements
	OG0000 OG0011 OG0023 OG003

WBC [D28] Within (N=101,98,96,98,98,97)

Title	Measurements
	OG00098 OG00192 OG00292 OG003

WBC [D28] Above (N=101,98,96,98,98,97)

Title	Measurements
	OG0001 OG0013 OG0021 OG003

WBC [D28] Unknown (N=101,98,96,98,98,97)

Title	Measurements
	OG0002 OG0012 OG0020 OG003

WBC [D42] Below (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0014 OG0022 OG003

WBC [D42] Within (N=101,97,95,95,96,97)

Title	Measurements
	OG000100 OG00191 OG00292 OG003

WBC [D42] Above (N=101,97,95,95,96,97)

Title	Measurements
	OG0001 OG0012 OG0021 OG003

WBC [D42] Unknown (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

WBC [D63] Below (N=100,95,95,95,97,97)

Title	Measurements
	OG0001 OG0012 OG0021 OG003

WBC [D63] Within (N=100,95,95,95,97,97)

Title	Measurements
	OG00098 OG00192 OG00293 OG003

WBC [D63] Above (N=100,95,95,95,97,97)

Title	Measurements
	OG0001 OG0011 OG0021 OG003

WBC [D63] Unknown (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

WBC [D182] Below (N=99,91,88,91,93,97)

Title	Measurements
	OG0002 OG0012 OG0024 OG003

WBC [D182] Within (N=99,91,88,91,93,97)

Title	Measurements
	OG00093 OG00187 OG00282 OG003

WBC [D182] Above (N=99,91,88,91,93,97)

Title	Measurements
	OG0004 OG0012 OG0022 OG003

WBC [D182] Unknown (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

Title

Denominators

Categories

LYM [D0] Below (N=102,104,102,100,101,102)

Title	Measurements
	OG0000 OG0012 OG0020 OG0030 OG0040 OG0050

LYM [D0] Within (N=102,104,102,100,101,102)

Title	Measurements
	OG000100 OG001101 OG002102 OG003

LYM [D0] Above (N=102,104,102,100,101,102)

Title	Measurements
	OG0000 OG0011 OG0020 OG003

LYM [D0] Unknown (N=102,104,102,100,101,102)

Title	Measurements
	OG0002 OG0010 OG0020 OG003

LYM [D7] Below (N=102,101,100,99,100,99)

Title	Measurements
	OG0001 OG0010 OG0021 OG003

LYM [D7] Within (N=102,101,100,99,100,99)

Title	Measurements
	OG000100 OG001100 OG00299 OG003

LYM [D7] Above (N=102,101,100,99,100,99)

Title	Measurements
	OG0001 OG0010 OG0020 OG003

LYM [D7] Unknown (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0011 OG0020 OG003

LYM [D21] Below (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0011 OG0020 OG003

LYM [D21] Within (N=101,100,97,97,99,99)

Title	Measurements
	OG000101 OG00198 OG00294 OG003

LYM [D21] Above (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

LYM [D21] Unknown (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0011 OG0023 OG003

LYM [D28] Below (N=101,98,96,98,98,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

LYM [D28] Within (N=101,98,96,98,98,97)

Title	Measurements
	OG00099 OG00196 OG00295 OG003

LYM [D28] Above (N=101,98,96,98,98,97)

Title	Measurements
	OG0000 OG0010 OG0021 OG003

LYM [D28] Unknown (N=101,98,96,98,98,97)

Title	Measurements
	OG0002 OG0012 OG0020 OG003

LYM [D42] Below (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0012 OG0020 OG003

LYM [D42] Within (N=101,97,95,95,96,97)

Title	Measurements
	OG000101 OG00195 OG00295 OG003

LYM [D42] Above (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

LYM [D42] Unknown (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

LYM [D63] Below (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

LYM [D63] Within (N=100,95,95,95,97,97)

Title	Measurements
	OG000100 OG00195 OG00295 OG003

LYM [D63] Above (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

LYM [D63] Unknown (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

LYM [D182] Below (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0011 OG0020 OG003

LYM [D182] Within (N=99,91,88,91,93,97)

Title	Measurements
	OG00098 OG00190 OG00288 OG003

LYM [D182] Above (N=99,91,88,91,93,97)

Title	Measurements
	OG0001 OG0010 OG0020 OG003

LYM [D182] Unknown (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

MON [D0] Below (N=102,104,102,100,101,102)

Title	Measurements
	OG00011 OG00118 OG00226 OG003

MON [D0] Within (N=102,104,102,100,101,102)

Title	Measurements
	OG00089 OG00186 OG00275 OG003

MON [D0] Above (N=102,104,102,100,101,102)

Title	Measurements
	OG0000 OG0010 OG0021 OG003

MON [D0] Unknown (N=102,104,102,100,101,102)

Title	Measurements
	OG0002 OG0010 OG0020 OG003

MON [D7] Below (N=102,101,100,99,100,99)

Title	Measurements
	OG00020 OG00114 OG00222 OG003

MON [D7] Within (N=102,101,100,99,100,99)

Title	Measurements
	OG00082 OG00186 OG00278 OG003

MON [D7] Above (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

MON [D7] Unknown (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0011 OG0020 OG003

MON [D21] Below (N=101,100,97,97,99,99)

Title	Measurements
	OG00025 OG00120 OG00220 OG003

MON [D21] Within (N=101,100,97,97,99,99)

Title	Measurements
	OG00076 OG00179 OG00274 OG003

MON [D21] Above (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

MON [D21] Unknown (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0011 OG0023 OG003

MON [D28] Below (N=101,98,96,98,98,97)

Title	Measurements
	OG00017 OG00119 OG00226 OG003

MON [D28] Within (N=101,98,96,98,98,97)

Title	Measurements
	OG00082 OG00177 OG00270 OG003

MON [D28] Above (N=101,98,96,98,98,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

MON [D28] Unknown (N=101,98,96,98,98,97)

Title	Measurements
	OG0002 OG0012 OG0020 OG003

MON [D42] Below (N=101,97,95,95,96,97)

Title	Measurements
	OG00016 OG00119 OG00220 OG003

MON [D42] Within (N=101,97,95,95,96,97)

Title	Measurements
	OG00085 OG00178 OG00275 OG003

MON [D42] Above (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

MON [D42] Unknown (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

MON [D63] Below (N=100,95,95,95,97,97)

Title	Measurements
	OG00017 OG00120 OG00221 OG003

MON [D63] Within (N=100,95,95,95,97,97)

Title	Measurements
	OG00082 OG00175 OG00273 OG003

MON [D63] Above (N=100,95,95,95,97,97)

Title	Measurements
	OG0001 OG0010 OG0021 OG003

MON [D63] Unknown (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

MON [D182] Below (N=99,91,88,91,93,97)

Title	Measurements
	OG00017 OG00120 OG00220 OG003

MON [D182] Within (N=99,91,88,91,93,97)

Title	Measurements
	OG00082 OG00171 OG00268 OG003

MON [D182] Above (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

MON [D182] Unknown (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

NEU [D0] Below (N=102,104,102,100,101,102)

Title	Measurements
	OG0001 OG0014 OG0024 OG003

NEU [D0] Within (N=102,104,102,100,101,102)

Title	Measurements
	OG00098 OG00198 OG00297 OG003

NEU [D0] Above (N=102,104,102,100,101,102)

Title	Measurements
	OG0001 OG0012 OG0021 OG003

NEU [D0] Unknown (N=102,104,102,100,101,102)

Title	Measurements
	OG0002 OG0010 OG0020 OG003

NEU [D7] Below (N=101,100,98,97,97,97)

Title	Measurements
	OG0002 OG0012 OG0022 OG003

NEU [D7] Within (N=101,100,98,97,97,97)

Title	Measurements
	OG00096 OG00194 OG00294 OG003

NEU [D7] Above (N=101,100,98,97,97,97)

Title	Measurements
	OG0003 OG0013 OG0022 OG003

NEU [D7] Unknown (N=101,100,98,97,97,97)

Title	Measurements
	OG0000 OG0011 OG0020 OG003

NEU [D21] Below (N=101,100,97,97,99,99)

Title	Measurements
	OG0003 OG0015 OG0022 OG003

NEU [D21] Within (N=101,100,97,97,99,99)

Title	Measurements
	OG00097 OG00192 OG00291 OG003

NEU [D21] Above (N=101,100,97,97,99,99)

Title	Measurements
	OG0001 OG0012 OG0021 OG003

NEU [D21] Unknown (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0011 OG0023 OG003

NEU [D28] Below (N=101,98,96,98,98,97)

Title	Measurements
	OG0001 OG0015 OG0023 OG003

NEU [D28] Within (N=101,98,96,98,98,97)

Title	Measurements
	OG00098 OG00189 OG00292 OG003

NEU [D28] Above (N=101,98,96,98,98,97)

Title	Measurements
	OG0000 OG0012 OG0021 OG003

NEU [D28] Unknown (N=101,98,96,98,98,97)

Title	Measurements
	OG0002 OG0012 OG0020 OG003

NEU [D42] Below (N=101,97,95,95,96,97)

Title	Measurements
	OG0003 OG0014 OG0021 OG003

NEU [D42] Within (N=101,97,95,95,96,97)

Title	Measurements
	OG00098 OG00191 OG00294 OG003

NEU [D42] Above (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0012 OG0020 OG003

NEU [D42] Unknown (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

NEU [D63] Below (N=100,95,95,95,97,97)

Title	Measurements
	OG0001 OG0011 OG0021 OG003

NEU [D63] Within (N=100,95,95,95,97,97)

Title	Measurements
	OG00098 OG00193 OG00294 OG003

NEU [D63] Above (N=100,95,95,95,97,97)

Title	Measurements
	OG0001 OG0011 OG0020 OG003

NEU [D63] Unknown (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

NEU [D182] Below (N=99,91,88,91,93,97)

Title	Measurements
	OG0003 OG0013 OG0024 OG003

NEU [D182] Within (N=99,91,88,91,93,97)

Title	Measurements
	OG00093 OG00186 OG00283 OG003

NEU [D182] Above (N=99,91,88,91,93,97)

Title	Measurements
	OG0003 OG0012 OG0021 OG003

NEU [D182] Unknown (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

PLA [D0] Below (N=102,104,102,100,101,102)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

PLA [D0] Within (N=102,104,102,100,101,102)

Title	Measurements
	OG000100 OG001104 OG002102 OG003

PLA [D0] Above (N=102,104,102,100,101,102)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

PLA [D0] Unknown (N=102,104,102,100,101,102)

Title	Measurements
	OG0002 OG0010 OG0020 OG003

PLA [D7] Below (N=102,101,100,99,100,99)

Title	Measurements
	OG0001 OG0010 OG0020 OG003

PLA [D7] Within (N=102,101,100,99,100,99)

Title	Measurements
	OG000101 OG001100 OG002100 OG003

PLA [D7] Above (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

PLA [D7] Unknown (N=102,101,100,99,100,99)

Title	Measurements
	OG0000 OG0011 OG0020 OG003

PLA [D21] Below (N=101,100,97,97,99,99)

Title	Measurements
	OG0001 OG0010 OG0021 OG003

PLA [D21] Within (N=101,100,97,97,99,99)

Title	Measurements
	OG000100 OG00199 OG00293 OG003

PLA [D21] Above (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

PLA [D21] Unknown (N=101,100,97,97,99,99)

Title	Measurements
	OG0000 OG0011 OG0023 OG003

PLA [D28] Below (N=101,98,96,98,98,97)

Title	Measurements
	OG0002 OG0010 OG0020 OG003

PLA [D28] Within (N=101,98,96,98,98,97)

Title	Measurements
	OG00098 OG00196 OG00296 OG003

PLA [D28] Above (N=101,98,96,98,98,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

PLA [D28] Unknown (N=101,98,96,98,98,97)

Title	Measurements
	OG0001 OG0012 OG0020 OG003

PLA [D42] Below (N=101,97,95,95,96,97)

Title	Measurements
	OG0001 OG0011 OG0020 OG003

PLA [D42] Within (N=101,97,95,95,96,97)

Title	Measurements
	OG000100 OG00196 OG00293 OG003

PLA [D42] Above (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0021 OG003

PLA [D42] Unknown (N=101,97,95,95,96,97)

Title	Measurements
	OG0000 OG0010 OG0021 OG003

PLA [D63] Below (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0011 OG0021 OG003

PLA [D63] Within (N=100,95,95,95,97,97)

Title	Measurements
	OG000100 OG00194 OG00294 OG003

PLA [D63] Above (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

PLA [D63] Unknown (N=100,95,95,95,97,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

PLA [D182] Below (N=99,91,88,91,93,97)

Title	Measurements
	OG0002 OG0011 OG0021 OG003

PLA [D182] Within (N=99,91,88,91,93,97)

Title	Measurements
	OG00097 OG00190 OG00287 OG003

PLA [D182] Above (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

PLA [D182] Unknown (N=99,91,88,91,93,97)

Title	Measurements
	OG0000 OG0010 OG0020 OG003

Title

Denominators

Categories

Flu A/BRI/59/07 H1N1

Title	Measurements
	OG000145.1(115.9 to 181.6) OG001215.7(168.2 to 276.5) OG003158.7(127.9 to 197.1)

Flu A/Uru/716/07 H3N2

Title	Measurements
	OG000175.7(129.6 to 238.2) OG001183.5(135.2 to 248.9) OG003191.4(138.4 to 264.7)

Flu B/Bri/60/08

Title	Measurements
	OG000662.1(545.4 to 803.8) OG001658.3(540.2 to 802.0) OG003576.1(479.8 to 691.8)

Title

Denominators

Categories

Flu A/Brisbane/59/07 H1N1

Title	Measurements
	OG000145.1(115.9 to 181.6) OG001215.7(168.2 to 276.5) OG002226.3(181.4 to 282.2)

Flu A/Uru/716/07 H3N2

Title	Measurements
	OG000175.7(129.6 to 238.2) OG001183.5(135.2 to 248.9) OG002181.7(128.1 to 257.9)

Flu B/Brisbane/60/08

Title	Measurements
	OG000662.1(545.4 to 803.8) OG001658.3(540.2 to 802.0) OG002478.8(389.5 to 588.6)

Title

Denominators

Categories

Flu A/BRI/59/07 H1N1

Title	Measurements
	OG000145.1(115.9 to 181.6) OG001215.7(168.2 to 276.5) OG005166.9(132.5 to 210.3)

Flu A/Uru/716/07 H3N2

Title	Measurements
	OG000175.7(129.6 to 238.2) OG001183.5(135.2 to 248.9) OG005221.9(167.2 to 294.6)

Flu B/Bri/60/08

Title	Measurements
	OG000662.1(545.4 to 803.8) OG001658.3(540.2 to 802.0) OG005688.1(593.0 to 798.6)

Title

Denominators

Categories

Flu A/Bri/59/07 H1N1

Title	Measurements
	OG000145.1(115.9 to 181.6) OG001215.7(168.2 to 276.5) OG004137.4(109.0 to 173.1)

Flu A/Uru/716/07 H3N2

Title	Measurements
	OG000175.7(129.6 to 238.2) OG001183.5(135.2 to 248.9) OG004216.1(160.0 to 292.0)

Flu B/Bri/60/08

Title	Measurements
	OG000662.1(545.4 to 803.8) OG001658.3(540.2 to 802.0) OG004644.9(534.5 to 778.2)

Title

Denominators

Categories

Flu A/Cal H1N1 [at Day 0] (N=92;86;92;88;91;91)

Title	Measurements
	OG00014.6(11.2 to 19.0) OG00110.9(8.7 to 13.6) OG00213.0(10.2 to 16.5) OG00310.7(8.2 to 14.0) OG0049.3(7.7 to 11.4) OG00510.1(8.2 to 12.5)

Flu A/Cal H1N1 [at Day 21] (N=92;86;92;89;91;91)

Title	Measurements
	OG00031.1(24.0 to 40.3) OG00126.3(19.9 to 34.8) OG002277.3(222.4 to 345.7) OG003

Flu A/Cal H1N1 [at Day 42] (N=92;86;92;89;91;91)

Title	Measurements
	OG000238.6(191.8 to 296.7) OG001396.2(329.2 to 476.8) OG002271.2(224.6 to 327.4) OG003

Flu A/Cal H1N1 [at Day 63] (N=92;86;92;89;91;91)

Title	Measurements
	OG000254.2(210.1 to 307.7) OG001645.2(557.6 to 746.6) OG002245.0(200.7 to 299.1) OG003

Title

Denominators

Categories

Title	Measurements
	OG000136.6(108.6 to 171.9) OG001206.9(171.3 to 249.9) OG002151.7(119.1 to 193.2) OG003171.7(143.2 to 205.8) OG004218.5(169.8 to 281.1) OG005323.6(268.8 to 389.5)

Title

Denominators

Categories

Flu A/Bri/59/07 H1N1

Title	Measurements
	OG00276 OG00370 OG00450 OG00533 OG006145

Flu A/Uru/716/07 H3N2

Title	Measurements
	OG00272 OG00376 OG00473 OG005

Flu B/Bri/60/08

Title	Measurements
	OG00274 OG00378 OG00471 OG005

Title

Denominators

Categories

Flu A/Bri/59/07 H1N1

Title	Measurements
	OG00289 OG00382 OG00481 OG00587 OG006170

Flu A/Uru/716/07 H3N2

Title	Measurements
	OG00277 OG00379 OG00481 OG005

Flu B/Bri/60/08

Title	Measurements
	OG00290 OG00389 OG00491 OG005

Title

Denominators

Categories

Flu A/Bri/59/07 H1N1

Title	Measurements
	OG00212.0(9.4 to 15.4) OG0039.6(7.7 to 12.1) OG0044.2(3.5 to 5.0) OG0053.1(2.5 to 3.9) OG00610.3(8.6 to 12.3)

Flu A/Uru/716/07 H3N2

Title	Measurements
	OG00220.6(14.8 to 28.6) OG00319.3(14.2 to 26.4) OG00417.3(12.8 to 23.2) OG005

Flu B/Bri/60/08

Title	Measurements
	OG00210.5(8.3 to 13.5) OG00314.3(11.0 to 18.7) OG0048.6(7.0 to 10.7) OG005

Title

Denominators

Categories

Flu A/Bri/59/07 H1N1 [Day 21 or 42 after dose 1]

Title	Measurements
	OG00071 OG00174 OG00276 OG00370 OG00417 OG00528

Flu A/Bri/59/07 H1N1 [Day 63 after dose 1]

Title	Measurements
	OG00063 OG00176 OG00269 OG003

Flu A/Uru/716/07 H3N2 [Day 21 or 42 after dose 1]

Title	Measurements
	OG00072 OG00173 OG00272 OG003

Flu A/Uru/716/07 H3N2 [Day 63 after dose 1]

Title	Measurements
	OG00071 OG00169 OG00269 OG003

Flu B/Bri/60/08 [Day 21 or 42 after dose 1]

Title	Measurements
	OG00076 OG00176 OG00274 OG003

Flu B/Bri/60/08 [Day 63 after dose 1]

Title	Measurements
	OG00073 OG00173 OG00267 OG003

Title

Denominators

Categories

Flu A/Bri/59/07 H1N1

Title	Measurements
	OG00045 OG00157 OG00245 OG00338 OG00446 OG00554

Flu A/Uru/716/07 H3N2

Title	Measurements
	OG00058 OG00156 OG00254 OG003

Flu B/Bri/60/08 Victoria

Title	Measurements
	OG00068 OG00154 OG00248 OG003

Title

Denominators

Categories

Flu A/Bri/59/07 H1N1 [at Day 0]

Title	Measurements
	OG00020 OG00118 OG00226 OG00318 OG00423 OG00520

Flu A/Bri/59/07 H1N1 [Days 21 or 42 post dose 1]

Title	Measurements
	OG00086 OG00184 OG00289 OG003

Flu A/Bri/59/07 H1N1 [at Day 63 post dose 1]

Title	Measurements
	OG00084 OG00186 OG00285 OG003

Flu A/Uru/716/07 H3N2 [at Day 0]

Title	Measurements
	OG00012 OG00116 OG0028 OG003

Flu A/Uru/716/07 H3N2 [Days 21 or 42 post dose 1]

Title	Measurements
	OG00078 OG00177 OG00277 OG003

Flu A/Uru/716/07 H3N2 [at Day 63 post dose 1]

Title	Measurements
	OG00078 OG00175 OG00273 OG003

Flu B/Bri/60/08 [at Day 0]

Title	Measurements
	OG00062 OG00150 OG00256 OG003

Flu B/Bri/60/08 [Days 21 or 42 post dose 1]

Title	Measurements
	OG00091 OG00185 OG00290 OG003

Flu B/Bri/60/08 [at Day 63 post dose 1]

Title	Measurements
	OG00091 OG00186 OG00291 OG003

Title

Denominators

Categories

Flu A/Bri/59/07 H1N1

Title	Measurements
	OG00063 OG00174 OG00266 OG00361 OG00467 OG00571

Flu A/Uru/716/07 H3N2

Title	Measurements
	OG00066 OG00164 OG00260 OG003

Flu B/Bri/60/08 Victoria

Title	Measurements
	OG00090 OG00188 OG00279 OG003

Title

Denominators

Categories

Flu A/Bri/59/07 H1N1 [Day 21 or 42 post dose 1]

Title	Measurements
	OG0008.4(6.5 to 10.8) OG00112.9(10.0 to 16.6) OG00212.0(9.4 to 15.4) OG0039.6(7.7 to 12.1) OG0042.3(1.9 to 2.6) OG0053.2(2.7 to 3.8)

Flu A/Bri/59/07 H1N1 [at Day 63 post dose 1]

Title	Measurements
	OG0006.9(5.4 to 8.9) OG00111.2(9.1 to 13.7) OG0028.4(6.6 to 10.6) OG003

Flu A/Uru/716/07 H3N2 [Day 21 or 42 post dose 1]

Title	Measurements
	OG00017.4(13.0 to 23.3) OG00115.5(11.8 to 20.4) OG00220.6(14.8 to 28.6) OG003

Flu A/Uru/716/07 H3N2 [at Day 63 post dose 1]

Title	Measurements
	OG00013.3(10.0 to 17.6) OG00111.7(9.1 to 15.0) OG00215.0(11.2 to 19.9) OG003

Flu B:Bri/60/08 [Day 21 or 42 post dose 1]

Title	Measurements
	OG00012.6(9.8 to 16.2) OG00113.9(11.1 to 17.5) OG00210.5(8.3 to 13.5) OG003

Flu B/Bri/60/08 [at Day 63 post dose 1]

Title	Measurements
	OG0009.6(7.5 to 12.4) OG00110.0(8.1 to 12.2) OG0027.9(6.3 to 9.9) OG003

Title

Denominators

Categories

Flu A/Bri/59/07 H1N1

Title	Measurements
	OG0004.0(3.1 to 5.3) OG0015.2(4.2 to 6.6) OG0024.7(3.7 to 6.0) OG0033.7(2.9 to 4.8) OG0044.4(3.5 to 5.4) OG0055.0(4.0 to 6.3)

Flu A/Uru/716/07 H3N2

Title	Measurements
	OG0009.0(6.7 to 11.9) OG0017.2(5.6 to 9.3) OG0029.7(7.2 to 13.1) OG003

Flu B/Bri/60/08 Victoria

Title	Measurements
	OG0006.7(5.2 to 8.6) OG0015.7(4.5 to 7.1) OG0025.5(4.3 to 6.9) OG003

Title

Denominators

Categories

Flu A/Bri/59/07 H1N1 [at Day 0]

Title	Measurements
	OG00017.3(14.1 to 21.3) OG00116.7(13.8 to 20.2) OG00218.8(15.2 to 23.3) OG00316.2(12.8 to 20.6) OG00414.6(12.0 to 17.8) OG00516.6(13.7 to 20.0)

Flu A/Bri/59/07 H1N1 [at Day 21 or 42]

Title	Measurements
	OG000145.1(115.9 to 181.6) OG001215.7(168.2 to 276.5) OG002226.3(181.4 to 282.2) OG003

Flu A/Bri/59/07 H1N1 [at Day 63]

Title	Measurements
	OG000120.2(96.5 to 149.7) OG001186.5(150.4 to 231.4) OG002157.0(126.0 to 195.8) OG003

Flu A/Uru/716/07 H3N2 [at Day 0]

Title	Measurements
	OG00010.1(8.1 to 12.5) OG00111.8(9.7 to 14.4) OG0028.8(7.4 to 10.6) OG003

Flu A/Uru/716/07 H3N2 [at Day 21 or 42]

Title	Measurements
	OG000175.7(129.6 to 238.2) OG001183.5(135.2 to 248.9) OG002181.7(128.1 to 257.9) OG003

Flu A/Uru/716/07 H3N2 [at Day 63]

Title	Measurements
	OG000134.4(100.4 to 179.9) OG001138.4(104.8 to 182.7) OG002132.0(94.9 to 183.7) OG003

Flu B/Bri/60/08 [at Day 0]

Title	Measurements
	OG00052.6(41.8 to 66.3) OG00147.3(38.0 to 58.9) OG00245.4(36.0 to 57.4) OG003

Flu B/Bri/60/08 [at Day 21 or 42]

Title	Measurements
	OG000662.1(545.4 to 803.8) OG001658.3(540.2 to 802.0) OG002478.8(389.5 to 588.6) OG003

Flu B/Bri/60/08 [at Day 63]

Title	Measurements
	OG000506.7(422.3 to 608.0) OG001471.2(396.3 to 560.2) OG002359.6(299.4 to 431.9) OG003

Title

Denominators

Categories

Flu A/Bri/59/07 H1N1

Title	Measurements
	OG00068.5(53.6 to 87.4) OG00189.2(71.0 to 112.0) OG00287.4(68.5 to 111.5) OG00364.6(51.4 to 81.1) OG00464.6(51.4 to 81.1) OG00583.7(66.0 to 106.2)

Flu A/Uru/716/07 H3N2

Title	Measurements
	OG00089.5(65.8 to 121.8) OG00187.7(64.0 to 120.3) OG00287.1(61.4 to 123.5) OG003

Flu B/Bri/60/08 Victoria

Title	Measurements
	OG000339.9(276.7 to 417.5) OG001273.8(228.7 to 327.9) OG002245.4(197.8 to 304.3) OG003

ID	Term
D012141	Respiratory Tract Infections
D007239	Infections
D009976	Orthomyxoviridae Infections
D012327	RNA Virus Infections
D014777	Virus Diseases
D012140	Respiratory Tract Diseases